Article

CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects.

Transplantation Division, Department of Surgery, University of California, San Francisco, CA, USA.
American Journal of Transplantation (Impact Factor: 6.19). 07/2007; 7(6):1457-63. DOI: 10.1111/j.1600-6143.2007.01829.x
Source: PubMed

ABSTRACT The involvement of CD4(+)CD25(+) regulatory T cells (Treg) in general immune homeostasis and protection from autoimmune syndromes is now well established. Similarly, there has been increasing evidence for Treg involvement in allograft rejection and current immunotherapies. However, despite significant advances in understanding the development, function, and therapeutic efficacy of Treg in certain well-defined rodent models, the relevance of Treg to clinical transplantation remains unclear. In this review, we summarize our current understanding of the role of Treg in immunity and organ transplantation in experimental and clinical settings. In addition, we review advances in using Treg as a form of immune therapy. The goal is to highlight the complexities and opportunities in the field and to provide evidence to support the use of antigen-specific Tregs in the context of transplantation to facilitate a robust and selective state of immune tolerance.

Full-text

Available from: Qizhi Tang, Jan 13, 2015
1 Follower
 · 
78 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Memory T (Tm) cells pose a major barrier to long-term transplant survival. Whether regulatory T cells (Tregs)can control them remains poorly defined. Previously,we established that double-negative (DN) Tregs suppress effector T (Teff) cells. Here, we demonstrate that DNTregs effectively suppress CD4+/CD8+Teff and CD8+Tm but not CD4+Tm cells, whereas the suppression on CD8+Tm is abrogated by perforin (PFN) deficiency in DNTregs. Consistently, in a BALB/c to B6-Rag1-/-skin transplantation, transfer of DN Tregs suppressed the rejection mediated by CD4þ/CD8+Teff and CD8+Tmcells (76.0±4.9, 87.5±5.0 and 63.0±4.7 days, respectively)but not CD4þTmcells (25.3±1.4 days). Both CD8þ effector memory T and central memory T compartments significantly reduced after DN Treg transfer. CD4+Tm highly expresses granzyme B (GzmB) inhibitor serine protease inhibitor-6 (Spi6). Spi6 deficiency renders CD4þTm susceptible to DN Treg suppression. In addition,transfer of WT DN Tregs, but not PFN-/-DN Tregs,inhibited the skin allograft rejection mediated by Spi6-/-CD4þTm(75.5±7.9 days). In conclusion, CD4+ and CD8+Tm cells differentially respond toDNTregs’ suppression.The GzmB resistance conferred by Spi6 in CD4þTm cells might hint at the physiological significance of Tmpersistence
    American Journal of Transplantation 03/2014; 14(3):580-93. DOI:10.1111/ajt.12614 · 6.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although the immunomodulative properties of mesenchymal stem cells (MSCs) open up attractive possibilities in solid-organ transplantation, information concerning the optimal dose, route, timing of administration, major histocompatibility complex (MHC)-restriction and relevant mechanisms is currently lacking. Therefore, better characterization of MSC immunoregulatory activity and elucidation of its mechanisms are crucial. In this study, we confirmed that MSCs did not elicit proliferation by allogeneic CD4(+) T cells, suggesting that MSCs were not immunogenic. By using C57BL/6 mouse MSCs as donor-derived or recipient-derived or as third-party MSCs, we discovered that MSCs suppressed CD4(+) T cell proliferation and prolonged mouse cardiac allograft survival in a dose-dependent and non-MHC-restricted manner. We also found that intraperitoneal administration favored survival prolongation, although this prolongation was weaker than that via the intravenous route. Only infusion at earlier time points favored survival prolongation. Depletion of CD4(+)CD25(+) T cells did not affect the immunosuppression of MSCs on CD4(+) T cells. Moreover, MSCs did not induce regulatory T cells. The in vivo data revealed that MSCs did not increase the percentage of CD4(+)CD25(+) T cells and FoxP3 expression. More importantly, we demonstrated for the first time that depletion of CD4(+)CD25(+) T cells did not hinder MSC-induced survival prolongation, indicating that CD4(+)CD25(+) regulatory T cells were not essential for the prolongation of MSC-mediated allograft survival.
    Cell and Tissue Research 08/2014; 358(2). DOI:10.1007/s00441-014-1956-z · 3.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction. CD8 h CD57 + T-cell subpopulation and its functionally diff erent subsets play an important role in antitumour immunity. Th e relation of competitive subsets may infl u-ence the overall eff ect of CD8 h CD57 + T-cell mediated antitumour immunity and determine an individual response to antitumour immunotherapy. Th e aim of this study was to evalu-ate the proportion of cytotoxic, immunomodulating and immunosuppressive subsets of the CD8 h CD57 + T-cell subpopulation in the peripheral blood of cancer patients and age-matched healthy controls. Materials and methods. We studied the expression of biomarkers representing the cy-totoxic (perforin), immunosuppressive (FOXP3, NKG2A) and immunomodulating (IFNγ) properties of CD8 + CD57 + T cells in the peripheral blood of 49 cancer patients: 30 with clear cell renal cell carcinoma (age median 58, range 43–81), 19 with high risk cutaneous melanoma (age median 68, range 45–86) and 26 controls (age median 55, range 41–81) by multicolour fl ow cytometry. Results. Th e percentage of immunosuppressive CD8 h CD57 + FOXP3 + T-cell subset in CD8 h CD57 + T-cell population varied. It was absent in 65% of controls, while only 23% and 26% of such patients were observed in renal cell carcinoma (RCC) and melanoma groups, respectively. Even 40% of RCC and 37% of melanoma patients had a high percentage of CD8 h CD57 + FOXP3 + T-cell subset, while in the control group we found no such subjects. Th e cytotoxic CD8 h CD57 + Perforin + T-cell subset was signifi cantly increased in RCC patients, but showed no relevant rise in melanoma patients, whereas the immunomodulat-ing CD8 h CD57 + IFNγ + subset was signifi cantly increased in melanoma patients but showed no relevant rise in RCC patients when compared to controls. Conclusions. Th e amount of various functionally diff erent subsets in CD8 h CD57 + T-cell subpopulation varies greatly among cancer patients. Th ese diff erences may infl uence the overall CD8 h CD57 + T-cell mediated antitumour immune response and determine an individual response to antitumour immunotherapy.